All posts by imreal

Medicus Healthcare Solutions Promotes Heather Croke to Chief People Officer


Heather Croke

Medicus Healthcare Solutions, a leading locum tenens staffing company focused on making a difference in the lives of others, announced the promotion of Heather Croke to Chief People Officer. In this new role, Heather, who has led the People Team since 2021, will continue to drive the company’s core people strategy and operations as a member of the C-Suite. As Chief People Officer, Heather will provide strategic direction for human resources, learning and development, talent acquisition, internal communications, and employee engagement.

Heather joined Medicus in 2012 as a Contracts Manager. Her legal background and role with our clients and providers served her well in providing a foundation for her operational knowledge within the staffing space. In 2016, Heather was promoted to Director of Human Resources and Risk Management which further leveraged Heather’s experience and skillset. In her current role as Vice President of People, Risk, and Strategy, Heather has played a critical role in progressing Medicus’ “People First, Always” approach, ensuring that Medicus is a top employer in the State of New Hampshire and is a workplace where our employees can thrive.

“A Company like Medicus doesn’t succeed without its most valuable resource – people. Our people are our differentiator. Under Heather’s direction, we have built – and will continue to develop – a culture that is vital to our Company’s success,” said Bob Dickey, Chief Executive Officer. “As a trusted advisor and an integral member of our leadership team, Heather has aligned our people strategy with the Company’s strategic initiatives and will continue to do so in this new role.”

Recently, under Heather’s leadership, Medicus earned the DecisionWise Employee Engagement Top Performer Award. This award spotlights organizations that have finished in the top 10% for overall employee engagement scores in 3 company size tiers: less than 1,000 employees, 1,000-4,999 employees, and 5,000+ employees.

About Medicus Healthcare Solutions

Medicus Healthcare Solutions has been connecting physicians and advanced practice providers to medical groups, practices, health systems, hospitals, and other facilities throughout the United States since 2004. Since then, Medicus has expanded its services to include transition projects, medicusOne – a vendor management system/managed service provider-hybrid offering – resource management services, and consulting services. Through its proprietary solutions and methodologies, including mSolve, Medicus has built a reputation for its unique and highly personalized approach to physician staffing. With nearly 300 employees nationwide, Medicus Healthcare Solutions is one of the fastest-growing companies in the healthcare staffing industry. To learn more, go to http://www.medicushcs.com.

Share article on social media or email:

Heartbeat Named to “Inclusive Workplace” List by Best Companies Group


Creating a place where people feel heard, seen, and like they belong—where they can be their true selves—is one of the most important things we can do as an organization.

Leading healthcare marketing agency Heartbeat has been recognized as an “Inclusive Workplace” by Best Companies Group, a workplace culture and employee engagement expert, and COLOR Magazine, a leader in corporate inclusivity. Heartbeat is the only healthcare-focused advertising agency to be named to the distinguished company listing.

Selection for the Inclusive Workplace listing is based on employee feedback gathered from a thorough and independent survey that gauges employee perceptions on workplace inclusion and belonging. Companies are evaluated based on their survey results, and only those that score high enough are eligible for the prestigious honor.

“This recognition is solely based on Heartbeat employees’ direct and honest feedback. And their employees have spoken: Heartbeat is truly committed and excelling at creating a workplace environment that makes people feel included, like they belong, and as a truly important part of their organization,” said Jaime Raul Zepeda, Executive Vice President at Best Companies Group. “Heartbeat is ahead of its peers by putting people first. We are proud to celebrate their excellence!”

The Inclusive Workplace recognition is the latest workplace award for Heartbeat, which continues to establish itself as one of the premier organizations for culture and employee experience. The company now boasts multiple selections to the Ad Age and MM+M Best Places to Work lists, as well as a Diversity & Inclusion Champion award from Med Ad News.

“Creating a place where people feel heard, seen, and like they belong—where they can be their true selves—is one of the most important things we can do as an organization,” said Michelle Edwards, Heartbeat’s Vice President of Human Resources & Operations. “Diversity, equity, and inclusion are woven into the very fabric of Heartbeat. It’s a part of our everyday decision-making, how we interact and collaborate with each other, and who we are as both individuals and a larger community.”

The full Best Companies Group Inclusive Workplace list can be found at https://bestcompaniesgroup.com/programs/inclusive-workplace-program/recognition-list-2022/.

ABOUT HEARTBEAT

Heartbeat is a full-service agency for healthcare Challenger Brands. Challengers are playing a high-stakes game—they must battle behemoth market leaders, upend ingrained treatment habits, or transform a “me-too” product into “yes-please.”

The agency is known for serving up distinctive strategies and differentiating approaches, ensuring clients’ market positions are uniquely owned. Heartbeat designs its organization around a “100% Integration” model, housing media, strategy, med comms, creative, technology, and even point of care/population health under the same roof for the tightest, most integrated campaigns possible. It prices work based on outcomes, not outputs. Its innovative model delivers not only alignment but also powerful orchestration, greater efficiency, and maximum impact for every dollar spent—all the necessary elements for Challengers to triumph.

That’s the philosophy, here’s the creds: nearly 300 employees between NYC & LA; multiple agency leaders with decades of tenure; a pile of awards from the likes of the MANNYs, MM+M Awards, OMMAs, and Clios; an industry-leading commitment to diversity & inclusion (with a Med Ad News D&I Champion nod to match); and a President who dared to be quoted as follows, “We celebrate people who stand up and say, ‘You know what? This is dumb.’” Damn straight.

For more information about Heartbeat, please email marketing@weareheartbeat.com.

Share article on social media or email:

Dr. Rod J. Rohrich, Presents The Third Biennial Joseph G. Mccarthy Endowed Lectureship


Dallas plastic surgeon Dr. Rod J. Rohrich

Dallas plastic surgeon Dr. Rod J. Rohrich

“It is a distinct honor and privilege to be invited to present this Endowed Lectureship, named for the internationally known and highly respected plastic surgeon, Dr. Joseph McCarthy.”— Dr. Rod J. Rohrich

Dr. Rod J. Rohrich, a board certified plastic surgeon in Dallas, Texas , was invited to deliver the Third Biennial Joseph G. McCarthy Endowed Lectureship at NYU.

Dr. Rohrich delivered his talk entitled, ‘Consistency and Excellence in Plastic Surgery – A Career Pathway’, to the NYU Langone Health Plastic Surgery faculty, fellows and residents to expound upon the amazing contributions by Professor Joseph McCarthy while he was the chair of NYU Plastic Surgery. The presentation delineated the pathway for developing consistency and excellence in all of plastic surgery. Dr. Rohrich used his surgical specialty of rhinoplasty as an example to show how he has done this during his over 35 year career in plastic surgery.

This endowed professorship is named for Dr. McCarthy, the past chair of the department of plastic surgery at NYU. Dr. McCarthy is only the second chair of NYU Plastic Surgery in the department’s 57 year history. The current chair of the Department of Plastic Surgery at New York University, Dr. Edwardo Rodríguez, facilitated this endowed lectureship to honor Dr. McCarthy’s lifelong contributions to the field of plastic surgery and to the Department of Plastic Surgery at NYU.

Dr. Rohrich also delivered grand rounds, Innovations in Plastic Surgery that Transformed Cosmetic Surgery, in which he exemplified the numerous innovations that have been the hallmark and trademark of plastic surgery as illustrated by his development of a natural facial rejuvenation procedure – the Lift and Fill Facelift which is based upon discovery of the facial fat compartment by Dr. Rohrich and his colleagues. This discover has further enhanced the understanding of the science of facial aging and has allowed plastic surgeons to better understand how to perform a more natural facelift procedure based upon the specific aging of each patient’s face.

About Rod J. Rohrich, M.D., F.A.C.S.

Dr. Rod J. Rohrich is a board certified plastic surgeon in Dallas, Texas. He is considered one of the most influential plastic surgeons in this century. He was named the top plastic surgeon in America by Newsweek in both rhinoplasty and facelift surgery in 2021 and 2022. Dr. Rohrich is a Clinical Professor of Plastic Surgery at Baylor College of Medicine. He was the first Chair of the Department of Plastic Surgery as well as the first plastic surgeon selected as a Distinguished Teaching Professor at UT Southwestern Medical Center. He graduated from Baylor College of Medicine with high honors, and completed his plastic surgery training at the University of Michigan Medical Center and fellowships at Massachusetts General Hospital/Harvard (hand/microsurgery) and Oxford University (pediatric plastic surgery). He is Chair of the Dallas Rhinoplasty Meeting, Founding Chair of the Dallas Cosmetic Surgery and Medicine Meeting, Founding Member of the Alliance in Reconstructive Surgery, and a Founding Partner of the Dallas Plastic Surgery Institute.

He is the immediate (after serving for 18 years) past Editor-in-Chief of the most respected global peer reviewed plastic surgery journal – the Plastic and Reconstructive Surgery Journal. He is Founding Editor-in-Chief/Editor Emeritus of the first open access peer reviewed plastic surgery journal, PRS Global Open. Dr. Rohrich has published over 1000 peer reviewed articles and seven textbooks in plastic surgery including a best-selling medical book entitled The Facial Danger Zones. Dr. Rohrich recently published an innovative cosmetic surgery video atlas, Cosmetic Surgery by the Masters.

Dr. Rohrich also served as president of the American Society of Plastic Surgeons (ASPS), the largest organization of board certified plastic surgeons in the world. He repeatedly has been selected by his peers as one of America’s best doctors. He received the ASPS Special Achievement Award and on three occasions has received one of his profession’s highest honors, the Plastic Surgery Foundation (PSF) Distinguished Service Award, which recognizes his contributions to education in plastic surgery. In addition, he has been recognized by the PSF with the Plastic Surgery Foundation Distinguished Career Researcher Award for his contributions to plastic surgery research and innovations. He is also the recipient of the ASPS 2022 Honorary Citation.

Share article on social media or email:

Syner-G Biopharma Group Announces Karen Casey as Chief People Officer


Syner-G BioPharma Group (Syner-G), a leading provider of integrated pharmaceutical science and regulatory consulting services to the pharmaceutical and medical device industries, today announced that Karen Casey has joined the organization as the chief people officer.

“We are thrilled to welcome Karen Casey into the Syner-G family,” shared Syner-G BioPharma Group CEO, Ron Kraus. “We are a people business and to support our growth, we need an experienced leader to help build and retain a sophisticated workforce as well as build on our culture of excellence.”

”Casey has 27 years’ experience in human resources, operations and talent management spanning a variety of corporate sectors with a track record of building successful human resource functions. Her range of expertise includes building strategic HR functions across HR operations, talent management, and culture aligned with organizational strategy. Casey has a breadth of experience and demonstrated success across large, multinational consumer product companies and start-up organizations where she has created award-winning teams focused on company culture, talent acquisition, talent management and benefit design. She also ran her own consulting firm for 12 years.“

I am excited to join Syner-G as an integral part of the leadership team,” said Karen Casey, chief people officer. “This is an exciting time in the biopharma industry, and I look forward to building from an incredible talent pool and educational environment at Syner-G.”Read more about Karen Casey on LinkedIn here.

About Syner-G BioPharma Group

Based in Boston, MA, Syner-G is a leading provider of customized CMC, regulatory strategy, medical writing, regulatory submissions and publishing services, supporting pharmaceutical and biotechnology companies across the therapeutic spectrum and complete drug development lifecycle. For more information, please visit: https://synergbiopharma.com/

Share article on social media or email:

Colorado School for the Deaf and the Blind joins the Rocky Mountain…


The Colorado School for the Deaf and the Blind (CSDB) announced today that it has joined the Rocky Mountain E-Purchasing System, a regional purchasing group that helps local governments post,…

(PRWeb January 10, 2023)

Read the full story at https://www.prweb.com/releases/colorado_school_for_the_deaf_and_the_blind_joins_the_rocky_mountain_e_purchasing_system/prweb19102638.htm

Children’s Tumor Foundation Expands into a New Strategic Chapter as Impact Investor in NF Research


News Image

Topical MEK inhibitor NFX-179 Shows Promise in Shrinking Cutaneous Neurofibromas in NF1 Patients

The Children’s Tumor Foundation (CTF) entered a new phase in its strategic NF research model by announcing a significant impact investment in a Phase 2b clinical trial at NFlection Therapeutics, a biotechnology company focused on the discovery and development of effective, targeted therapies for rare disorders. The trial involves NFX-179, a topical (on the skin) treatment which has successfully passed a Phase 1/2a (safety and first signs of efficacy) trial. The current Phase 2b study will more rigorously test the drug’s safety and effectiveness.

The NFX-179 treatment is for cutaneous neurofibromas (cNF), which are tumors that grow in the skin or right underneath the skin, and result in severe, disfiguring bumps on the skin. The vast majority of NF1 patients have cNF that are responsible for significant negative effects on the quality of life, including pain, itching, and emotional / appearance concerns as a result of bullying or discrimination.

NFX-179 is a topical, metabolically labile, MEK inhibitor, which is the same mechanism used in the drug Koselugo (selumetinib), which has previously received FDA and EMA approval for inoperable plexiform neurofibromas. Koselugo is an oral drug that has systemic impact on the body. CTF was an early-stage funder of both animal and in-human studies that led to the discovery that MEK has the potential to shrink tumors.

This new use of MEK as a ‘soft’ topical inhibitor designed specifically for cutaneous neurofibromas is to impact locally while minimizing side effects. There is a high unmet need for this treatment. CTF is making a landmark impact investment in these next phase topical studies to help accelerate the development of this promising treatment, which should it prove successful, means more quickly delivering important life-changing treatments to patients.

CTF’s investment strategy in NF drug development is a diversified portfolio approach to tackling all forms of NF, from early-stage investments in young investigators to established academic initiatives in the Discovery Fund, to large-scale, open data collaboratives such as Synodos. CTF has operated as a strategic partner to all stakeholders who can help bring effective treatments to the patients. This first-in-its-history impact investment further establishes CTF as a co-investor with pharma/biotech in innovative NF research, expanding opportunities to increase the NF drug development pipeline.

“We’re thrilled to be working with NFlection on this incredible opportunity to bring life-changing treatments to NF patients,” said Annette Bakker, President of the Children’s Tumor Foundation. “CTF is mainly known as a seed funder, willing to take risk, and willing to put a lot of sweat equity to advance the science and the treatments. With our recent investments in science and pharma, we are sending a clear message that if we want to accelerate treatments, NF deserves serious funding. With the tremendous support of the CTF Board of Directors and the CTF Business Advisory Council, we are ready to demonstrate ‘skin-in-the-game’. This will hopefully increase confidence for others to invest in NF. NF research provides good return, both as a research investment for pharma and biotech, and most importantly, the ultimate return of better lives for the millions affected who are waiting for our help.”

“We’re thankful to the Children’s Tumor Foundation for this investment in our work,” said William Hodder, CEO of NFlection Therapeutics. “We believe – with good reason, based on our previous results – that this treatment has the potential to help so many. We’re also grateful for the connectivity CTF brings with this partnership to NF patients, clinics, and experts. It is known from other disease foundations that investments from medical research foundations like CTF may convince other investors that supporting NFlection is the right path forward.”

NF is a group of genetic disorders known as neurofibromatosis or schwannomatosis. It affects 1 in 3,000 births of all populations (about 2.5 million worldwide), and can cause deafness, blindness, bone abnormalities, disabling pain, learning disabilities, and cancer.

Over the past decade, CTF has worked to grow the NF field, which in addition to expanding partnerships with academic researchers, public/government researchers and funders, now has a growing number of pharma/biotech companies in the space. In addition to NFlection, they include Alexion/AstraZeneca, Takeda, SpringWorks, Novartis, Vivace, Pfizer, Healx, and NF2 Therapeutics, just to name a few.

Gabriel Groisman, Chairman of CTF’s Board of Directors said: “The evolution of NF research has come so far in recent years, thanks in large part to the herculean efforts of the Children’s Tumor Foundation. With this investment, we are taking the first step in our new approach to ending NF. The Foundation’s Board of Directors and the Business Advisory Council have made the bold decision that it’s time to start directly investing in select impact opportunities in the private sector that have the potential of bringing relief to NF patients as quickly as possible. Pharma and biotech can now look to CTF as a true partner, not just for knowledge and access to stakeholders, but also as a strategic investor. We at CTF are all in to find treatments and ultimately a cure for NF.”

Thanks to the generous connections of CTF Business Advisory Council (BAC) member Trinna Cuellar, as well as the BAC’s chairmen Alex Zisson and Randall Stanicky, CTF is very grateful for the pro bono legal advice from Wilson Sonsini Goodrich & Rosati on this impact investment.

To learn more about NF and CTF, please visit ctf.org.

To learn about partnership and investment opportunities with CTF, please contact info@ctf.org.

Share article on social media or email:

Schaus Dental Studio Announces New Website, Biologically and Technologically Advanced Services


Schaus Dental Studio in Golden Valley, MN

Schaus Dental Studio in Golden Valley, MN

“BioRejuvenation dentistry is one of the most cutting-edge and promising approaches to restoring mouths to a healthy state. It is based on years of biological research, which shows that rehabilitating a patient’s mouth to an optimal position has lasting oral and overall health benefits.”

Dr. Paul Schaus, the founder of Schaus Dental Studio, serving Hennepin County has launched a new website (https://www.schausdentalstudio.com), which highlights the practice’s specialty in BioRejuvenation services, and digital dentistry technologies. A former naval dentist, Dr. Schaus’ concierge practice in the suburbs of Minneapolis is at the forefront of emerging dental technologies, leveraging both the power of the human body and the power of technology to provide a premium patient experience.

Harnessing the body’s natural ability to heal and restore itself to optimal health lies at the root of BioRejuvenation dentistry. Dr. Schaus specializes in this proactive, yet conservative treatment which restores teeth to their original, youthful shape, all the while optimizing the function of the mouth.

“BioRejuvenation dentistry is one of the most cutting-edge and promising approaches to restoring mouths to a healthy state. It is based on years of biological research, which shows that rehabilitating a patient’s mouth to an optimal position has lasting oral and overall health benefits,” Dr. Schaus said.

Using minimally invasive methods to restore the natural biology of each person’s dental system, the goal of BioRejuvenation dentistry is to achieve a proper balance between the upper and lower teeth. Once this balance is achieved the need for costly restorations in the future is mitigated. Treatments involved in BioRejuvenation of the mouth and teeth may include treatment for TMJ disorders, bite alignment, and the restoration of individual teeth.

Ultimately, this rehabilitation results in relief from pain, improved dental function, and an aesthetically improved smile, all the while setting the stage for excellent oral health in the future. “We promote BioRejuvenation because it allows our patients to break cycles of lifelong dental disease,” he explained.

BioRejuvenation is supported and complemented by Digital Dentistry, which Schaus Dental Studio also embraces. “Advances in technology offer greater accuracy and precision for screening, diagnosis, implant surgeries and restorative techniques. They also offer a more comfortable, expedited experience for patients,” Dr. Schaus said. Digital technologies used at Schaus Dental Studio include digital x-rays, intra-oral cameras, 3D digital scanning replacing impressions and computer-assisted design (CAD) of restorations and appliances.

In addition, digital screens are located in each practice area, which Dr. Schaus uses to educate patients about various problems, and what they can expect from various procedures. Wi-Fi is also available in the office, and patients can request appointments online by visiting the practice’s new website.

At Schaus Dental Studio, Dr. Schaus and his team provide preventative screenings and cleanings, and dental restorations including dental implants, crowns, and bridges. He also provides cosmetic treatments including teeth whitening, porcelain veneers, and dental implants.

For more information visit https://www.schausdentalstudio.com or call 763-525-0306. Schaus Dental Studio is located at 7575 Golden Valley Road Suite 240, Golden Valley, MN 55427.

About Paul V. Schaus DDS

Dr. Paul V. Schaus graduated from the University of Minnesota School of Dentistry. He then entered the United States Navy Dental Corps, serving service members aboard the aircraft carrier USS Theodore Roosevelt. His service included a deployment to the Middle East. Before opening Schaus Dental Studio in Golden Valley, Dr. Schaus had a private dental practice in Oak Grove, MN.

Share article on social media or email:

Laurent Clerc National Deaf Education Center at Gallaudet University Launches New Online Community, Deaf Education Resource Center for Families and Educators


Laurent Clerc National Deaf Education Center

The Laurent Clerc National Deaf Education Center (Clerc Center) at Gallaudet University announced this week the public launch of the Clerc Center Online Community, a unique online resource center advancing the education of deaf children and young adults.

The Clerc Center Online Community, now open to the public, is a direct extension of the Clerc Center, a federally-funded national deaf education center, and supports its mission to ensure that the diverse population of deaf and hard of hearing students from birth through age 21 in the nation are educated and empowered to maximize their full potential as productive and contributing members of society.

The Online Community is designed to serve multiple audiences including parents and families with deaf and hard of hearing children, early childhood interventionists and development specialists, educational professionals, and healthcare providers. Its goal is to serve as a supportive community and the leading centralized hub where families and deaf education professionals can network with one another and secure expert resources and informed choices for their ongoing work with deaf children.

The Online Community includes resources to go; online training and learning; networking with others; live events; and ongoing support. Among the many resources visitors can find at the Online Community are several learning modules, including Advocacy for Your Child; Fifteen Principles for Reading to Deaf Children; Multilingual Families and Homes; and K-12 ASL Content Standards.

Since its founding in 1969, the Clerc Center (formerly Gallaudet University’s Pre-College National Mission Programs) with its two model and demonstration schools, the Kendall Demonstration Elementary School (KDES) and the Model Secondary School for the Deaf (MSSD), has served as a leading institution in best practices for the advancement of deaf education in pre-college settings.

“We are very pleased to officially launch the Clerc Center Online Community to the public,” said Marianne Belsky, the Chief Academic Officer of the Clerc Center. “The Online Community meets a longstanding need for a centrally accessible site where families and professionals alike can go to take advantage of the Clerc Center’s deep portfolio of resources and expertise in deaf education. They will also find resources from partnering organizations that the Clerc Center works with to encourage growth and advancement of excellence in deaf education.”

Nicole Sutliffe, the Chief Administrative Officer of the Clerc Center, added, “We know that still today many parents, families, and educators are wanting and looking for guidance on how to support their ability to provide the very best in deaf education for their students and children. We are very excited that starting today, we now have the perfect home to deliver this to our allies throughout the U.S. and beyond.”

About the Clerc Center

The Laurent Clerc National Deaf Education Center (Clerc Center) at Gallaudet University is a federally funded center with exemplary elementary and secondary education programs for deaf and hard of hearing students and is tasked with developing and disseminating innovative curricula, instructional techniques, and products nationwide while providing information, training, and technical assistance for parents and professionals to meet the needs of deaf and hard of hearing students from birth to age 21. More information about the Clerc Center can be found at http://clerccenter.gallaudet.edu/

Media Contacts:

Tyrone Giordano, Director of Communications, Clerc Center

tyrone.giordano@gallaudet.edu / 202-572-9213

Robert B. Weinstock, Senior Public Relations Manager, Gallaudet University

robert.weinstock@gallaudet.edu / 202-250-2411

Share article on social media or email:

Hood College to Receive $1M from 2023 Omnibus Appropriations Bill


News Image

“I am grateful for the support of our US Senators from Maryland for these innovative research centers. Building on Hood’s academic strengths in these areas, the new facilities will enable students and faculty to address local and global challenges.” said Hood President Andrea E. Chapdelaine, Ph.D.

Hood College will receive $1 million from congressionally directed spending via the Fiscal Year 2023 Omnibus Appropriations Bill, secured by U.S. Senators Ben Cardin and Chris Van Hollen (D-Md.), to fund two new centers: the Marlene Grossnickle Young ’76, H’14, P’09 and Michael S. Young, P’09 Data Driven Frederick Center (DDF) and the Biomedical Research and Training Center.

Funding for these projects comes from congressionally directed spending requested by Senators Cardin and Van Hollen and enacted as part of the fiscal year 2023 omnibus government funding bill.

Previously called earmarks, congressionally directed spending has returned for a second year after a ten-year hiatus, allowing members of Congress to present important projects in their state or district for consideration by the Appropriations Committee. Cardin and Van Hollen presented these projects to the Appropriations Committee as investments designed to benefit the State of Maryland and the Frederick community.

Together, Senators Cardin and Van Hollen secured $36.5 million in congressionally directed spending for education and workforce development projects throughout the state of Maryland in the FY23 omnibus. This funding further advances Hood College’s Forging the Future campaign, which has raised nearly $64.7 million toward its $65 million goal.

“On behalf of the Hood and Frederick community, I am grateful for the support of our U.S. Senators from Maryland for these innovative research centers. Building on Hood’s historic and growing academic strengths in these areas, the new facilities will enable our students and faculty to help address both local and global challenges in partnership with Frederick biomedical research and manufacturing industries, government, businesses and nonprofits,” said Hood College President Andrea E. Chapdelaine, Ph.D. “Undergraduate and graduate students, as well as our partners’ employees, will acquire cutting-edge, high-demand skills that will address regional workforce needs, further strengthening the scope and quality of Hood’s educational offerings.”

“Investing in STEM education is key to equipping Marylanders with the tools they need to tackle 21st-century challenges and compete for 21st-century jobs. The direct federal funding we delivered for Hood College will address both sides of that equation by enhancing research efforts and training students to succeed in industries of the future. With these funds, Hood College will help unlock more opportunity for students in our state,” said Senator Van Hollen.

“I’m proud to support these two federal investments that bolster Hood College’s ability to serve two identified needs for the Frederick community in supporting nonprofit organizations and the biomedical workforce,” said Senator Cardin. “This funding will help to establish these distinct centers that will have the dual benefit of training Hood College students with the skills necessary for the region’s in-demand professions while providing a benefit to local community organizations.”

For more information on Data Driven Frederick and the Biomedical Research and Training Center, click here to view the full release on Hood’s website.

About Hood College

Hood College is an independent, liberal arts college, offering more than 30 bachelor’s degrees, four pre-professional programs, 19 master’s degree programs, two doctorates and 10 post-baccalaureate certificates. Located in historic Frederick, near Washington, D.C., Baltimore and the I-270 technology corridor, Hood gives students access to countless internships and research opportunities.

Share article on social media or email: